Diabetes & Endocrinologygut microbiomeincretins
Duodenal Recombinant RORDEP1 Was Safe and Triggered Early Incretin-Insulin Responses in Healthy Men
By MedXY|May 26, 2026
In a randomized crossover trial, short-term duodenal r-RORDEP1 infusion was well tolerated and produced early changes in GLP-1, GIP, insulin, C-peptide, glucose, and a measure of insulin sensitivity in healthy men.